Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (9): 1371-1375.
• Review • Previous Articles Next Articles
Received:2025-10-11
Online:2026-09-30
Published:2026-11-16
| [1] Ginès P, Krag A, Abraldes J G, et al. Liver cirrhosis[J]. Lancet, 2021,398(10308):1359-1376. [2] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020,396(10258):1204-1222. [3] Liu Y B, Chen M K. Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions[J]. World J Gastroenterol, 2022,28(41):5910-5930. [4] Yi Q, Yang J, Wu Y, et al. Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells[J]. Front Immunol, 2023,14:1204524. [5] Danielsen K V, Wiese S, Busk T, et al. Cardiovascular mapping in cirrhosis from the compensated stage to hepatorenal syndrome: a magnetic resonance study[J]. Am J Gastroenterol, 2022,117(8):1269-1278. [6] Simbrunner B, Mandorfer M, Trauner M, et al. Gut-liver axis signaling in portal hypertension[J]. World J Gastroenterol, 2019,25(39):5897-5917. [7] Tilg H, Adolph T E, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications[J]. Cell Metab, 2022,34(11):1700-1718. [8] Anand S, Mande S S. Host-microbiome interactions: gut-liver axis and its connection with other organs[J]. NPJ Biofilms Microbiomes, 2022,8(1):89. [9] Fukui H. Leaky gut and gut-liver axis in liver cirrhosis: clinical studies update[J]. Gut Liver, 2021,15(5):666-676. [10] Odenwald M A, Turner J R. The intestinal epithelial barrier: a therapeutic target?[J]. Nat Rev Gastroenterol Hepatol, 2017,14(1):9-21. [11] Pellegrini C, Fornai M, D'Antongiovanni V, et al. The intestinal barrier in disorders of the central nervous system[J]. Lancet Gastroenterol Hepatol, 2023,8(1):66-80. [12] Ding C, Wang Z, Dou X, et al. Farnesoid X receptor: from structure to function and its pharmacology in liver fibrosis[J]. Aging Dis, 2024,15(4):1508-1536. [13] Xu X, Lu F, Yu D, et al. Cortex Dictamni induces cholestatic liver injury via the bile acid-gut-liver axis mediated by FXR signaling pathway in rats[J]. J Ethnopharmacol, 2025,351:120019. [14] Simbrunner B, Hofer B S, Schwabl P, et al. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence[J]. Hepatol Int, 2024,18(3):929-942. [15] Leshem A, Liwinski T, Elinav E. Immune-microbiota interplay and colonization resistance in infection[J]. Mol Cell, 2020,78(4):597-613. [16] Barbaro M R, Cremon C, Morselli-Labate A M, et al. Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity[J]. Gut, 2020,69(11):1966-1974. [17] Luo X, Wang K, Jiang C. Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis: function, mechanism, and therapeutic prospects[J]. Cell Host Microbe, 2025,33(6):836-853. [18] Violi F, Nocella C, Bartimoccia S, et al. Gut dysbiosis-derived low-grade endotoxemia: a common basis for liver and cardiovascular disease[J]. Kardiol Pol, 2023,81(6):563-571. [19] Xirouchakis E, Pelekanos A, Xirouchakis S, et al. A systematic review of microbiota in cirrhosis: a change towards a more pathogenic predisposition[J]. Int J Mol Sci, 2025,26(2):527. [20] Qin X, Chen M, He B, et al. Role of short-chain fatty acids in non-alcoholic fatty liver disease and potential therapeutic targets[J]. Front Microbiol, 2025,16:1539972. [21] Gao Y, Yao Q, Meng L, et al. Double-side role of short chain fatty acids on host health via the gut-organ axes[J]. Anim Nutr, 2024,18:322-339. [22] Shang H, Huang C, Xiao Z, et al. Gut microbiota-derived tryptophan metabolites alleviate liver injury via AhR/Nrf2 activation in pyrrolizidine alkaloids-induced sinusoidal obstruction syndrome[J]. Cell Biosci, 2023,13(1):127. [23] Andreu-Sánchez S, Ahmad S, Kurilshikov A, et al. Unraveling interindividual variation of trimethylamine N-oxide and its precursors at the population level[J]. iMeta, 2024,3(3):e183. [24] Wang M, Li XS, Wang Z, et al. Trimethylamine N-oxide is associated with long-term mortality risk: the multi-ethnic study of atherosclerosis[J]. Eur Heart J, 2023,44(18):1608-1618. [25] Zhang H, Tang M, Liu Q, et al. PAT exposure caused human hepatocytes apoptosis and induced mice subacute liver injury by activating oxidative stress and the ERS-associated PERK pathway[J]. Sci Total Environ, 2024,955:177003. [26] Guan H, Zhang X, Kuang M, et al. The gut-liver axis in immune remodeling of hepatic cirrhosis[J]. Front Immunol, 2022,13:946628. [27] Andrikopoulos P, Aron-Wisnewsky J, Chakaroun R, et al. Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide[J]. Nat Commun, 2023,14(1):5843. [28] McGettigan B, Hernandez-Tejero M, Malhi H, et al. Immune dysfunction and infection risk in advanced liver disease[J]. Gastroenterology, 2025,168(6):1085-1100. [29] Sobolev V, Tchepourina E, Soboleva A, et al. PPAR-γ in melanoma and immune cells: insights into disease pathogenesis and therapeutic implications[J]. Cells, 2025,14(7):534. [30] Yang Y, Yang L, Wu J, et al. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: a systematic review and network meta-analysis[J]. Clin Nutr, 2024,43(6):1224-1239. [31] Lee S Y, Lee S B, Kwon G H, et al. Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease[J]. J Microbiol, 2025,63(2):e2411002. [32] Huang L, Yu Q, Peng H, et al. Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2022,101(51):e32335. [33] Saeed H, Díaz L A, Gil-Gómez A, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease[J]. Clin Mol Hepatol, 2025,31(Suppl):S94-S111. [34] Zhang C, Zhang Q, Zhang X, et al. Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial[J]. Clin Nutr, 2025,44:248-258. [35] Mantri A, Köhlmoos A, Schelski D S, et al. Impact of synbiotic intake on liver metabolism in metabolically healthy participants and its potential preventive effect on metabolic-dysfunction-associated fatty liver disease (MAFLD): a randomized, placebo-controlled, double-blinded clinical trial[J]. Nutrients, 2024,16(9):1300. [36] Vallianou N, Stratigou T, Christodoulatos G S, et al. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives[J]. Curr Obes Rep, 2020,9(3):179-192. [37] Yuan Q, Fang Y, Guo J, et al. Therapeutic potential and mechanisms of rifaximin in ameliorating iron overload-induced ferroptosis and liver fibrosis in vivo and in vitro[J]. Toxicol Appl Pharmacol, 2024,484:116845. [38] Sanyal A J, Kowdley K V, Reau N S, et al. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence[J]. Hepatol Commun, 2024,8(6):e0436. [39] Yang W, Guo G, Sun C. Therapeutic potential of rifaximin in liver diseases[J]. Biomed Pharmacother, 2024,178:117283. [40] Idalsoaga F, Robles C, Ortiz A, et al. Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy[J]. Therap Adv Gastroenterol, 2024,17:17562848241254267. [41] Teklemariam A D, Al Hindi R, Qadri I, et al. Phage cocktails-an emerging approach for the control of bacterial infection with major emphasis on foodborne pathogens[J]. Biotechnol Genet Eng Rev, 2024,40(1):36-64. [42] Gan L, Feng Y, Du B, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae[J]. Nat Commun, 2023,14(1):3215. [43] Shah Y R, Ali H, Tiwari A, et al. Role of fecal microbiota transplant in management of hepatic encephalopathy: current trends and future directions[J]. World J Hepatol, 2024,16(1):17-32. [44] Saha S, Schnabl B. Modulating the microbiome in chronic liver diseases-current evidence on the role of fecal microbiota transplantation[J]. Expert Rev Gastroenterol Hepatol, 2025,19(1):53-64. [45] Zeng J, Zhao D, Way G, et al. Intestinal mucosal mitochondrial oxidative phosphorylation worsens with cirrhosis progression and is ameliorated with fecal microbiota transplantation[J]. JCI Insight, 2025,10(4):e186649. [46] Abenavoli L, Maurizi V, Rinninella E, et al. Fecal microbiota transplantation in NAFLD treatment[J]. Medicina (Kaunas), 2022,58(11):1559. [47] Tun K M, Hong A S, Batra K, et al. A systematic review of the efficacy and safety of fecal microbiota transplantation in the treatment of hepatic encephalopathy and clostridioides difficile infection in patients with cirrhosis[J]. Cureus, 2022,14(5):e25537. [48] Sanyal A J, Lopez P, Lawitz E J, et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial[J]. Nat Med, 2023,29(2):392-400. [49] Ratziu V, Harrison S A, Loustaud-Ratti V, et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH[J]. J Hepatol, 2023,78(3):479-492. [50] Hu D Y, Wu M Y, Chen G Q, et al. Metabolomics analysis of human plasma reveals decreased production of trimethylamine N-oxide retards the progression of chronic kidney disease[J]. Br J Pharmacol, 2022,179(17):4344-4359. [51] Wu W K, Lo Y L, Chiu J Y, et al. Gut microbes with the gbu genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition[J]. Gut Microbes, 2025,17(1):2446374. [52] Zhou D, Zhang J, Xiao C, et al. Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis[J]. Front Immunol. 2022,13:964477. [53] Emidio N B, Meli R, Tran H N T, et al. Chemical synthesis of TFF3 reveals novel mechanistic insights and a gut-stable metabolite[J]. J Med Chem, 2021,64(13):9484-9495. [54] Hendrikx T, Duan Y, Wang Y, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice[J]. Gut, 2019,68(8):1504-1515. [55] Pasta A, Formisano E, Calabrese F, et al. From dysbiosis to hepatic inflammation: a narrative review on the diet-microbiota-liver axis in steatotic liver disease[J]. Microorganisms, 2025,13(2):241. [56] 中国研究型医院学会肝病(中西医结合)专业委员会病毒性肝炎学组,浙江省慢性肝病重症化精准诊治与规模转化重点实验室,陈永平. 肝硬化患者粪菌移植治疗指南[J]. 临床肝胆病杂志,2025,41(3):424-431. [57] Hamilton J R, Chen E, Perez B S, et al. In vivo human T cell engineering with enveloped delivery vehicles[J]. Nat Biotechnol, 2024,42(11):1684-1692. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||